Charles River plots 2020 opening of South San Francisco lab

Charles River
The new Charles River Accelerator and Development Lab in South San Francisco will sister its site in Cambridge, Massachusetts. (Charles River)

Charles River Laboratories International has penned “early 2020” for the opening of its Charles River Accelerator and Development Lab (aka CRADL) in South San Francisco.

This lab is slated to provide “flexible, turnkey vivarium rental space supported by Charles River’s technical, vivarium, and veterinary support expertise in key biohubs,” according to the biopharma services provider.

The rentals are designed to be offered out to pharma and biotech researchers to launch or expand their drug research programs. But more than at your average lab, clients also gain access to Charles River’s complete portfolio of integrated drug discovery resources.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“Managed by skilled technicians, every research model receives best-in-class care in secure, modern, regulatory-compliant facilities," the company says.

It has a similar and older setup in downtown Cambridge, Massachusetts, which offers rental vivarium space for emerging and well-established research institutions.

RELATED: Charles River Labs cuts jobs as it closes San Diego site

Charles River says, similar to its sister facility in Cambridge, CRADL South San Francisco will “focus on providing a turnkey vivarium solution and in vivo support services for researchers looking to divert more time and resources to their research.”  

Birgit Girshick, corporate executive vice president for discovery and safety assessment, biologics testing solutions and avian vaccine services at Charles River, said: “In the earliest days of research, reaching key milestones on time and on budget is paramount to a program’s success. CRADL offers researchers the ability to focus on their research. When clients are ready to progress their idea through the development pipeline, Charles River has the portfolio and scientific expertise to offer critical support.”

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.